ImpriMed, a precision medicine company, has expanded its oncology services to include human applications, targeting complex blood cancers such as multiple myeloma and acute myeloid leukemia. By integrating genomic analysis, ex vivo drug sensitivity testing, and AI, the company offers personalized treatment predictions. The expansion reflects ImpriMed’s goal to revolutionize cancer therapy through advanced technology, empowering oncologists to tailor treatments based on individual responses.
In addition, ImpriMed plans to present new findings on non-Hodgkin lymphoma treatment at the EHA-SfPM meeting in Copenhagen. This advancement marks a significant transition from veterinary oncology, where the company has previously focused on canine and feline cancers.
ImpriMed continues to innovate in the precision medicine space, applying AI-driven technologies to predict drug responses. Earlier this year, the company launched services for veterinary oncology, providing personalized drug response predictions for canine patients. With its growing focus on both human and veterinary oncology, ImpriMed aims to improve cancer care across species through personalized, data-driven approaches.
Click here to read the original news story.